NEW YORK, June 27, 2016—Kantar Health, a leading global healthcare consulting and market research firm, is pleased to announce that Senior Group Director David Hanlon won the 2016 President’s Award at EphMRA’s Annual Conference held last week in Frankfurt. EphMRA is a professional organization that develops and improves standards and techniques for market research in Europe in the field of health and healthcare.
The President’s Award is recognition of a person’s outstanding contribution to healthcare market research. EphMRA praised Hanlon for his “wisdom and practical approach” and his “enthusiasm for all aspects of pharma and healthcare market research.” Hanlon has had a long relationship with EphMRA, having been a member of its board and program committee and chairing sessions at the organization’s meetings, training sessions and conferences.
“David’s award is a fantastic achievement that is richly deserved,” said Michel Murino, CEO Europe, Kantar Health. “We at Kantar Health have long known about David’s amazing and innovative work in marketing insights and his passion for advancing our methods so that our clients can succeed. I’m very happy that he has received this recognition within the industry.”
Hanlon is well known for his quantitative expertise, particularly for his work in developing Kantar Health’s offering in conjoint, brand mapping, new product launch tracking and pricing research. Over the years, he has worked for most of the major pharmaceutical companies and across most therapy areas in both qualitative and quantitative research, being one of the few truly all-round market researchers.
“I joined the UK office in 1998 and remember David teaching me how to design and conduct conjoint and pricing studies,” said Stephen Potts, Managing Director, Kantar Health UK. “He really is one of the pioneers in healthcare market research. I am privileged to work with him and delighted that he has been recognized in this way by EphMRA.”
Hanlon is also a thought leader in pharmaceutical marketing insights. Read his article “10 Key Activities in Measuring and Communicating Pharma Product Launch Excellence.”
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. For more information, please visit www.kantarhealth.com.